Merck & Co., Inc. (NYSE:MRK), one of the largest pharmaceutical companies in the world, has lost 15% year-to-date on the ...

Neither the mid-stage nor the late-stage trial of Adagene’s drug needs an arm studying the drug as a monotherapy without Merck’s Keytruda, the company said.

Merck is tackling its looming “Keytruda cliff” with a bold $10 billion acquisition of Verona Pharma. The deal brings Ohtuvayre, a first-in-class COPD drug, into Merck’s portfolio as it looks to ...

Pembrolizumab, an anti-programmed death receptor-1 (PD-1) therapy, is currently approved under the brand name Keytruda ® for other gynecological cancers, including cervical cancer and endometrial ...

Exporting counterfeit medicines is a cruel business that robs ill people of any hope for relief. Cancer patients unknowingly ...

Merck MRK announced a definitive agreement to acquire Verona Pharma VRNA for approximately $10 billion. The deal will add ...

Two Indian nationals were sentenced to 30 months in prison for smuggling counterfeit cancer drugs into the US.

Merck’s recent acquisition announcement sends a strong signal regarding its urgency to tackle the impending Keytruda patent ...

Two brothers from India were sentenced to 30 months in prison after they were found guilty of trying to sell counterfeit, ...

A key patent for Merck’s blockbuster drug Keytruda will expire in 2028. The cancer therapy brought the company $29.5 billion ...

Merck & Co. Inc. (NYSE:MRK) is one of the most undervalued NYSE stocks to buy now. On July 9, Merck announced its acquisition ...

Merck said on Wednesday it will acquire UK-based Verona Pharma for about $10 billion, gaining a promising respiratory ...